Rituximab Therapy in Pulmonary Alveolar Proteinosis: A Rare Case ReportCorrespondence Address :
Mr. Mojtaba Babaei Zarch,
Shahid Sadoughi Hospital, Ebne-sina Street, Yazd, Iran.
Pulmonary Alveolar Proteinosis (PAP) is a rare disorder characterised by accumulation of surfactant in alveoli due to impaired surfactant clearance. Although, whole lung lavage is the standard treatment of PAP, rituximab has also been introduced as a therapeutic option for PAP. A 49-year-old female patient, a known case of PAP, came to the outpatient clinic complaining of exacerbation of dyspnoea. The patient was treated with rituximab four times in a year. Finally, the clinical status and spirometry tests showed improvement. Although, the main treatment for PAP is whole lung lavage, other therapeutic options may be useful too. According to the prior case reports and the present one, rituximab can be useful in treatment of PAP.
Anti-CD20 monoclonal antibody, Ground glass opacity, Surfactant
Fatemeh Aghaei Meybodi, Salar Khazani Fard, Mojtaba Babaei Zarch, Mostafa Babai. RITUXIMAB THERAPY IN PULMONARY ALVEOLAR PROTEINOSIS: A RARE CASE REPORT. Journal of Clinical and Diagnostic Research [serial online] 2018 April [cited: 2019 Nov 14 ]; 12:OD07-OD08. Available from
Date of Submission: Sep 07, 2017
Date of Peer Review: Nov 13, 2017
Date of Acceptance: Jan 19, 2018
Date of Publishing: Apr 01, 2018
FINANCIAL OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)